Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells

References

• Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005; 435:974 - 8; http://dx.doi.org/10.1038/nature03816; PMID: 15944714
   PubMed Web of Science ®Google Scholar
• Jafarnejad SM, Li G. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Cancer Metastasis Rev 2012; 31:55 - 73; http://dx.doi.org/10.1007/s10555-011-9329-5; PMID: 22095030
   PubMed Web of Science ®Google Scholar
• Orlando DA, Lin CY, Bernard A, Wang JY, Socolar JES, Iversen ES, Hartemink AJ, Haase SB. Global control of cell-cycle transcription by coupled CDK and network oscillators. Nature 2008; 453:944 - 7; http://dx.doi.org/10.1038/nature06955; PMID: 18463633
   PubMed Web of Science ®Google Scholar
• Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 2014; 4:a014357; http://dx.doi.org/10.1101/cshperspect.a014357; PMID: 24384812
   PubMed Web of Science ®Google Scholar
• Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14:2501 - 14; http://dx.doi.org/10.1101/gad.836800; PMID: 11018017
   PubMed Web of Science ®Google Scholar
• Huang Z, Traugh JA, Bishop JM. Negative control of the Myc protein by the stress-responsive kinase Pak2. Mol Cell Biol 2004; 24:1582 - 94; http://dx.doi.org/10.1128/MCB.24.4.1582-1594.2004; PMID: 14749374
   PubMed Web of Science ®Google Scholar
• Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008; 19:311 - 8; http://dx.doi.org/10.1016/j.semcdb.2008.08.010; PMID: 18765289
   PubMed Web of Science ®Google Scholar
• STAT3 Gene - GeneCards |P40763. Available at: http://www.genecards.org/cgi-bin/carddisp.pl?gene=STAT3&search=STAT3
   Google Scholar
• Haghikia A, Hoch M, Stapel B, Hilfiker-Kleiner D. STAT3 regulation of and by microRNAs in development and disease. JAKSTAT 2012; 1:143 - 50; http://dx.doi.org/10.4161/jkst.19573; PMID: 24058763
   PubMedGoogle Scholar
• Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359:1 - 16; http://dx.doi.org/10.1042/0264-6021:3590001; PMID: 11563964
   PubMed Web of Science ®Google Scholar
• Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156:885 - 98; http://dx.doi.org/10.1111/j.1476-5381.2008.00085.x; PMID: 19366350
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785 - 9; http://dx.doi.org/10.1038/378785a0; PMID: 8524413
   PubMed Web of Science ®Google Scholar
• King TD, Gandy JC, Bijur GN. The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels. Exp Cell Res 2006; 312:3693 - 700; http://dx.doi.org/10.1016/j.yexcr.2006.08.010; PMID: 16987514
   PubMed Web of Science ®Google Scholar
• Neal JW, Clipstone NA. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J Biol Chem 2001; 276:3666 - 73; http://dx.doi.org/10.1074/jbc.M004888200; PMID: 11063740
   PubMed Web of Science ®Google Scholar
• Hagen T, Vidal-Puig A. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem Biophys Res Commun 2002; 294:324 - 8; http://dx.doi.org/10.1016/S0006-291X(02)00485-0; PMID: 12051714
   PubMed Web of Science ®Google Scholar
• AKT2 Gene - GeneCards |P31751. Available at: http://www.genecards.org/cgi-bin/carddisp.pl?gene=AKT2
   Google Scholar
• Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008; 20:581 - 9; http://dx.doi.org/10.1016/j.cellsig.2007.10.018; PMID: 18023328
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3:245 - 52; http://dx.doi.org/10.1038/35060032; PMID: 11231573
   PubMed Web of Science ®Google Scholar
• Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A, Viglietto G. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 2005; 166:737 - 49; http://dx.doi.org/10.1016/S0002-9440(10)62295-X; PMID: 15743786
   PubMed Web of Science ®Google Scholar
• Katayama K, Fujita N, Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 2005; 25:5725 - 37; http://dx.doi.org/10.1128/MCB.25.13.5725-5737.2005; PMID: 15964826
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231 - 41; http://dx.doi.org/10.1016/S0092-8674(00)80405-5; PMID: 9346240
   PubMed Web of Science ®Google Scholar
• Sun S-C. The noncanonical NF-κB pathway. Immunol Rev 2012; 246:125 - 40; http://dx.doi.org/10.1111/j.1600-065X.2011.01088.x; PMID: 22435551
   PubMed Web of Science ®Google Scholar
• NFKB2 Gene - GeneCards | Q00653. Available at: http://www.genecards.org/cgi-bin/carddisp.pl?gene=NFKB2&search=NFKB
   Google Scholar
• Nuclear factor NF-kappa-B p105 subunit - Homo sapiens (Human). Available at: http://www.uniprot.org/uniprot/P19838
   Google Scholar
• Transcription factor p65 - Homo sapiens (Human). Available at: http://www.uniprot.org/uniprot/Q04206
   Google Scholar
• Guo X, Goessl E, Jin G, Collie-Duguid ES, Cassidy J, Wang W, O’Brien V. Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res 2008; 28:1A 9 - 14; PMID: 18383818
   PubMed Web of Science ®Google Scholar
• Leeuwen IMM Van. Cyclotherapy : opening a therapeutic window in cancer treatment Oncotarget 2012; 3:596–600.
   Google Scholar
• Blagosklonny MV. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget 2012; 3:601 - 7; PMID: 22802145
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. “Targeting the absence” and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307 - 12; http://dx.doi.org/10.4161/cc.7.10.6250; PMID: 18487952
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105:533 - 9; http://dx.doi.org/10.1172/JCI8625; PMID: 10683383
   PubMed Web of Science ®Google Scholar
• Rao B, van Leeuwen IMM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1:639 - 50; PMID: 21317459
   PubMed Web of Science ®Google Scholar
• Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009; 8:2810 - 8; http://dx.doi.org/10.4161/cc.8.17.9503; PMID: 19657224
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222 - 33; PMID: 21447859
   PubMed Web of Science ®Google Scholar